Psychopathological complications associated to recreational drug consumption;Complicaciones psicopatológicas asociadas al consumo de drogas recreativas

Adicciones

Volumn 15, Issue SUPPL. 2, 2003, Pages 217-231

  Sáiz Martínez, Pilar Alejandra ^a   Garcia Portilla Gonzalez, Paz ^a   Martínez Barrondo, Sara ^a   Bascarán Fernández, Ma Teresa ^a   Bousoño García, Manuel ^a   Bobes García, Julio ^a  

^a UNIVERSIDAD DE OVIEDO   (Spain)

Author keywords

Cognitive impairment; Ecstasy; MDMA; Mental disorders; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ILLICIT DRUG; RECREATIONAL DRUG; SEROTONIN; UNCLASSIFIED DRUG;

ATTENTION; COGNITIVE DEFECT; DELIRIUM; DEPERSONALIZATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG ABUSE; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; MENTAL DISEASE; NEUROTOXICITY; PANIC; PSYCHOSIS; REVIEW; WORKING MEMORY;

EID: 0346458814     PISSN: 02144840     EISSN: None     Source Type: Journal    
DOI: 10.20882/adicciones.463     Document Type: Review

References (101)

1. Alciati A, Scaramelli B, Fusi A, Butteri E, Cattaneo ML, Mellado C. Three cases of delirium after "ecstasy" ingestion. J Psychoactive Drugs 1999; 31: 167-170.
2. Allen RP, McCann UD, Ricaurte GA. Persistent effects of (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep 1993; 16: 560-564.
3. Bailly D. Troubles neuropsychiatriques liés à la MDMA ("ecstasy"). L'Encéphale 1999; XXV: 595-602.
4. Benazzi F, Mazzolo M. Psychiatric illness associated with "ecstasy" Lancet 1991; 338: 1520.
5. Bhattachary S, Powell JH. Recreational use of 3,4-methylenedioxymethamphetamine (MDMA) or "ecstasy": evidence for cognitive impairment. Psychol Med 2001; 31: 647-658.
6. Bobes J, González MP, Sáiz PA, González JC. Psicopatología y trastornos psiquiátricos relacionados con el uso de MDMA. En: Bobes J, Lorenzo P, Sáiz PA, eds. Extasis (MDMA): un abordaje comprehensivo. Barcelona: Masson, 1998.
7. Bobes J, Sáiz PA, González MP, Bascarán MT, Bousoño M, Ricaurte G et al. Use of MDMA and other illicit drugs by young adult males in Northern Spain. Eur Addict Res 2002; 8: 147-154.
8. Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 1998; 51: 1532-1537.
9. Boné I, Ramos P, Villalba P, valle J. Trastorno psicótico inducido por el consumo de éxtasis (MDMA). Actas Esp Psiquiatr 2000; 28: 61-65.
10. Braña B, González JC, Pedrero C. Síntomas psicóticos en consumidores de éxtasis. Actas de las XXIV Jornadas Nacional de Socidrogalcohol. Alicante, 13-15 de Marzo, 1997.
11. Calafat A, Stocco P, Mendes F, Simon J, van de Wijngaart G, Sureda MP et al. Characteristics and social representation of ecstasy in Europe. Valencia: IREFREA, 1998.
12. Cassidy G, Ballard CG. Psychiatric sequelae of MDMA (ecstasy) and related drugs. Irish J Psychol Medicine 1994; 11: 132-133.
13. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R et al. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a coregistered SPECT and MRI study. Psychiatry Res Neuroimaging 2000; 98: 15-28.
14. Cohen RS. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy"). Biol Psychiatry 1996; 39: 819-820.
15. Cohen RS, Cocores J. Neuropsychiatric manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy"). Prog Neuropsychopharmacol Biol Psychiatry 1997; 21: 727-734.
16. Colado MI, Green AR. A study of the mechanism of MDMA ("ecstasy")-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br J Pharmacol 1994; 111: 131-136.
17. Creighton FJ, Black DL, Hyde CE. Ecstasy psychosis and flashbacks. Br J Psychiatry 1991; 159: 713-715.
18. Croft RJ, Mackay AJ, Mills ATD, Gruzelier JGH. The relative contributions of ecstasy and cannabis to cognitive impairment. Psychopharmacology 2001; 153: 373-379.
19. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50: 873-880.
20. Curran HV, Travill RA. Mood and cognitive effects of 3,4-methylenedioximethamphetamine (MDMA, "Ecstasy"): weekend "high" followed by mid-week low. Addiction 1997, 92: 821-831.
21. Demirkiran M, Jankovic J, Dean JM. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol 1996; 19: 157-164.
22. Dowling GP. Human deaths and toxic reactions attributed to MDMA and MDEA. En: Peroutka SJ, ed. Ecstasy: The Clinical, Pharmacological and Neurotoxicological effects of the drug MDMA. Hingham, Mass: Kluwer Academic Publishers, 1990.
23. Ellis P, Schimmel P. Ecstasy abuse. M Z Med J 1989; 102: 358.
24. Fernández J, Alvarez E, Secades R, Jiménez JM, Cañada A, Donate I et al. Consumo de drogas de síntesis en estudiantes de secundaria del Principado de Asturias (España). Adicciones 2003; 15: 31-37.
25. Gamella FJ, Alvarez-Roldán A. Drogas de síntesis en España. Patrones y tendencias de adquisición y consumo. Madrid: DGPNSD, 1997.
26. Gamma A, Frei E, Lehmann D, Pascual RD, Hell D, Vollenweider FX. Mood state and brain electric activity in Ecstasy users. Neuroreport 2000; 11: 157-162.
27. Gerra G, Zaimovic A, Giucastro G, Maestri D, Monica C, Sartori R et al. Serotonergic function after 3,4-methylenedioxymethamphetamine ("Ecstasy") in humans. Int Clin Psychopharmacol 1998; 13: 1-9.
28. Gerra G, Zaimovic A, Ferri M, Zambelli U, Timpano M et al. Long-lasting effects of 3,4-methylenedioxymethamphetamine (Ecstasy) on serotonin system function in humans. Biol Psychiatry 2000; 47: 127-136.
29. Gouzoulis E, Borchardt D, Hermle L. A case of toxic psychosis induced by 'Eve'(3,4-Methylene-dioxyethylamphetamine). Arch Gen Psychiatry 1993; 50: 75.
30. Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000; 68: 719-725.
31. Granato P, Weill S, Revillon JJ. Ecstasy and dementia in a young subject. Eur Psychiatry 1997; 12: 369-371.
32. Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology 1995; 119: 247-260.
33. Greer G, Strassman RJ. Information on "Ecstasy." Am J Psychiatry 1985; 142: 1391.
34. Hayner GN, McKinney H. MDMA: the dark side of Ecstasy. J Psychoactive Drugs 1986; 18: 341-347.
35. Huckle P, Palmer D, Lester H, Huws D. Case report "Ecstasy - The road to psychosis?." BJ Clin Soc Psychiatry 1991; 8: 4-5.
36. Jansen K. Adverse psychological effects. En: Saunders N, ed. Ecstasy reconsidered. London: Saunders, 1997.
37. Keenan E, Gervin M, Dorman A, O'Connor JJ. Psychosis and recreational use of MDMA ("Ecstasy"). Irish J Psychol Medicine 1993; 10: 162-163.
38. Klugman A, Hardy S, Baldeweg T, Gruzelier J. Toxic effect of MDMA on brain serotonin neurons. Lancet 1999; 353: 1269-1271.
39. Kopelman MD, Reed LJ, Marsden P, Mayes AR, Jaldow E, Laing H et al. Amnesic syndrome and severe ataxia following the recreational use of 3,4-methylenedioxymethamphetamine (MDMA, «ecsrasy») and other substances. Neurocase 2001; 7: 423-432.
40. Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR.Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?. Am J Drug Alcohol Abuse 1992; 18: 331-341.
41. Landabaso MA, Jiménez JM, Sanz J. Tratamiento de los problemas psíquicos relacionados con el consumo de drogas de diseño (MDMA, éxtasis). Trastornos Adictivos 1999; 1: 110-116.
42. Lieb R, Schuetz CG, Pfister H, von Sydow K, Wittchen HU. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Dep 2002; 68: 195-207
43. MacInnes N, Handley SL, Harding GF. Former chronic methylenedioxymethamphetamine (MDMA, ecstasy) users report mild depressive symptoms. J Psychopharmacol 2001; 15: 181-186.
44. Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999; 290: 136-145.
45. Maxwell DL, Polkey MI, Henry JA. Hyponatraemia and catatonic stupor after taking "ecstasy." BMJ 1993; 307: 1399.
46. McCann UD, Ricaurte GA. Lasting neuropsychiatric sequelae of metylenedioxymathamphetamine ('Ecstasy') in recreational users. J Clinical Psychopharm 1991; 11: 302-305.
47. McCann UD, Ricaurte GA. MDMA ("Ecstasy") and panic disorder. Biol Psychiatry 1992; 32: 950-953.
48. McCann UD, Ridenour BS, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after 3,4-methylenedioxymethamphetamine (MDMA): A controlled study in humans. Neuropsychopharmacology 1994; 10: 129-138.
49. McCann UD, Ricaurte GA. Aproximación a la neurobiología y neurotoxicidad comparada inducida por la MDMA. En: Bobes J, Lorenzo P, Sáiz PA, eds. Extasis (MDMA): un abordaje comprehensivo. Barcelona: Masson, 1998.
50. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA («Ecstasy») on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-1437.
51. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. Cognitive performance in (±)-3,4-methylenedioxymethamphetamine (MDMA; «ecstasy») esers: a controlled study. Psychopharmacology 1999a; 143: 417-425.
52. McCann UD, Eligulashvili V, Mertl M, Murphy DL, Ricaurte GA. Altered neuroendocrine and behavioral responses to m-chlorophenylpiperazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology 1999b; 147: 56-65.
53. McGuire P, Fahy T. Chronic paranoid psychosis after misuse of MDMA ("Ecstasy"). BMJ 1991; 302: 697.
54. McGuire P, Fahy T. Flashbacks following MDMA. Br J Psychiatry 1992; 160: 276.
55. McGuire PK, Cope H, Fahy TA. Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ("Ecstasy"). British J Psychiatry 1994; 165: 391-395.
56. McGuire P. Long term psychiatric and cognitive effects of MDMA use. Toxicology Letters 2000; 112-113: 153-156.
57. McKenna DJ, Peroutka SJ. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine. J Neurochem 1990; 54: 14-22.
58. Milas M. Acute Psychosis with aggresive behavior as a consequence of MDMA (Ecstasy) consumption. Lijec Vjesn 2000; 122: 27-30.
59. Mishkin M. Memory in monkeys severely impaired by combined but not by separate removal of the amygdala and hippocampus. Nature 1978; 273: 297-298.
60. Morgan MJ. Lasting psychological sequelae of recreational use of MDMA ("Ecstasy"): controlled studies in humans. J Psychopharmacol 1998a; 12: 101-102.
61. Morgan MJ. Recreational use of Ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1999b; 19: 252-264.
62. Morgan MJ. Memory deficits associated with recrational use of "Ecstasy" (MDMA). Psychopharmacology 1999; 141: 30-36.
63. Morgan MJ. Ecstasy (MDMA): a review of its posible persistent psychological effects. Psychopharmacology 2000; 152: 230-248.
64. Morgan MJ, McFie L, Fleetwood LH, Robinson JA. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence. Psychopharmacology 2002; 159: 294-303.
65. Nuñez LA. Psicosis por éxtasis. A propósito de un caso. Adicciones 1994; 6: 301-307.
66. Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasy -long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 1999; 175: 186-188.
67. Pallanti S, Mazzi D. MDMA (Ecstasy) precipation of panic disorders. Biol Psych 1992; 32: 91-94.
68. Parrott AC, Lasky J. Ecstasy (MDMA) affects upon mood and cognition: before and after a Saturday night dance. Psychopharmacology 1998; 139: 261-268.
69. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA or "Ecstasy": evidence for memory deficits. J Psychopharmacol 1998; 12: 79-83.
70. Parrott AC, Sisk E, Turner JD. Psychobiological problems in heavy "Ecstasy" (MDMA) polydrug users. Drug Alcohol Depend 2000; 60: 105-110.
71. Parrott AC, Milani RM, Parmar R, Turner JJD. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 2001; 159: 77-82.
72. Peroutka SJ. Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Dordrecht: Kluwer, 1990.
73. Reneman L, Booij J, Schmand B, Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered serotonin neurotransmission. Psychopharmacology 2000; 148: 322-324.
74. Ricaurte GA, Finnegan KT, Irwin I, Langston JW. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: Preliminary observations. Ann N Y Acad Sci 1990; 600: 699-710.
75. Ricaurte GA, McCann UD. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Annals of the New York Academy of Science 1992; 648: 371-382.
76. Ricaurte GA, Martello AL, Katz JL, Martello MB. Lasting effects of (±)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: Neurochemical observations. J Pharmacol Exp Ther 1992; 261: 616-622.
77. Ricaurte GA, Yuan J, McCann UD. 3,4-Methylenedioxymetamphetamine ("Ecstasy")-induced neurotoxicity: studies in animals: Neuropsychobiology 2000; 42: 5-10.
78. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 2002; 297: 2260-2263.
79. Rodgers J. Cognitive performance amongst recreational users of ecstasy. Psychopharmacology 2000; 151: 19-24.
80. Sáiz PA, Gonzalez MP, Martinez S, Bascarán MT, Bousoño M, Bobes J. Aproximaciȯn terapéutica del uso-abuso de MDMA (éxtasis). Adicciones 2000; 12: 167-175.
81. Sáiz PA, González MP, Paredes B, Delgado J, Lopez JL, Martínez S et al. Consumo de MDMA (éxtasis) en estudiantes de secundaria. Adicciones 2001; 13: 159-171.
82. Sáiz PA, García-Portilla MP, Paredes B, Bobes J. Anfetaminas y drogas de síntesis. En: Bobes J, Casas M, Gutierrez M, eds. Manual de evaluación y tratamiento de drogodependencias. Barcelona: Psiquiatría Editores, 2003.
83. Sarter M, Markowitsch HJ. Involvement of the amygdala in learning and memory: a critical review, with emphasis on anatomical relations. Behav Neurosci 1985; 99: 342-380.
84. Schifano F. Chronic atypical psychosis associated with MDMA ("ecstasy") abuse. Lancet 1991; 338: 1335.
85. Schifano F, Magni G. MDMA ("Ecstasy") abuse: psychopathological features and craving for chocolate: a case series. Biol Psychiatry 1994; 36: 763-767.
86. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA (ecstasy) consumption in the context of polydrug abuse: a report of 150 patients. Drug Alcohol Depend 1998; 52: 85-90.
87. Semple DM, Ebmeier KP, Glabus ME, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA («ecstasy») users. Br J Psychiatry 1999; 175: 63-69.
88. Series H, Boeles S, Dorkins E, Peveler R. Psychiatric complications of ecstasy use. J Psychopharmacol 1994; 8: 60-61.
89. Siegel RK. MDMA. Nonmedical use and intoxication. J Psychoactive Drugs 1986; 18: 349-354.
90. Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of "Ecstasy" users and their experiences with the drug. Br J Addict 1992; 87: 1161-1172.
91. Spatt J, Glawar B, Mamoli B. A pure amnestic syndrome after MDMA ("Ecstasy") ingestion. J Neurol Neurosurg Psychiatry 1997; 62: 418-419.
92. Tuchtenhagen F, Daumann J, Norra C, Gobbele R, Becker S, Pelz S et al. High intensity dependence of auditory evoked dipole source activity indicated decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 2000; 22: 608-617.
93. Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M. Un cas d'ėpisode psychotique aigu après prise inique d'ecstasy. L'Encéphale 2001; XXVII: 198-202.
94. Van Kampen J, Katz M. Persistent psicosis after a single ingestión of "ecstasy." Psychosomatics 2001; 42: 525-527.
95. Verkes RJ, Gijsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M et al. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 2001; 153: 196-202.
96. Wareing M, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA ("ecstasy"). Br J Psychol 2000; 91: 181-188.
97. Whitaker-Azmitia PM, Aronson TA. "Ecstasy" (MDMA)-induced panic. Am J Psychiatry 1989; 146: 119.
98. Williams H, Meagher D, Galligan P. MDMA ("Ecstasy"); a case of possible drug-induced psychosis. Ir J Med Sci 1993; 162: 43-44.
99. Windhaber J, Maierhofer D, Dantendorfer K. Panic disorder induced by large doses of 3,4-methylenedioxymethamphetamine resolved by paroxetine. J Clin Psychopharmacol 1998; 18: 95-96.
100. Winstock AR. Chronic paranoid psychosis after misuse of MDMA. British Med J 1991; 302: 1150.
101. Wodarz N, Böning J. "Ecstasy" induced psychotic despersonalization syndrome. Nervenarzt 1993; 64 (7): 478-480.